Rapid progress in molecular targeted therapy for allergic diseases

In Allergology International Vol. 72, Issue 1, we offer four review articles under the title "Rapid progress in molecular targeted therapy for allergic diseases." The recent introduction of biologics into clinical practice has changed the treatment strategy for several allergic diseases, i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergology International 2023-01, Vol.72 (1), p.1-2
1. Verfasser: Nagase, Hiroyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In Allergology International Vol. 72, Issue 1, we offer four review articles under the title "Rapid progress in molecular targeted therapy for allergic diseases." The recent introduction of biologics into clinical practice has changed the treatment strategy for several allergic diseases, including asthma. As biologics act on specific molecules, selecting patients based on biomarkers related to the target molecule is critically important. However, in early clinical trials for biologics in asthma, patients were not recruited based on specific biomarkers, so the efficacy of various biologics could not be proven. For example, with regard to mepolizumab, patients with an eosinophilic phenotype were not specifically recruited, and its efficacy was not proven in the early trials. However, in a subsequent study recruiting patients with eosinophilic asthma, a significant decrease in exacerbation was proven, suggesting the importance of biomarker-based selection of patients for the application of biologics.
ISSN:1323-8930
1440-1592
DOI:10.1016/j.alit.2022.11.011